Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
Abstract Objective To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy for patients with high-volume disease metastatic hormone-sensitive prostate cancer. Methods 153 cases of high-volume disease metastatic hormone-sensitive prostate cancer in...
Автори: | Zhuifeng Guo, Xuwei Lu, Fan Yang, Liang Qin, Ning Yang, Jiawen Wu, Hang Wang |
---|---|
Формат: | Стаття |
Мова: | English |
Опубліковано: |
BMC
2022-08-01
|
Серія: | European Journal of Medical Research |
Предмети: | |
Онлайн доступ: | https://doi.org/10.1186/s40001-022-00773-1 |
Схожі ресурси
Схожі ресурси
-
Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
за авторством: Hu L, та інші
Опубліковано: (2020-06-01) -
Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
за авторством: Kenichi Hata, та інші
Опубліковано: (2022-11-01) -
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
за авторством: Whi-An Kwon, та інші
Опубліковано: (2019-05-01) -
Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
за авторством: İlkay Gültürk, та інші
Опубліковано: (2022-11-01) -
Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
за авторством: S. V. Popov
Опубліковано: (2019-12-01)